Murrayanine Induces Cell Cycle Arrest, Oxidative Stress, and Inhibition of Phosphorylated p38 Expression in A549 Lung Adenocarcinoma Cells

Background: Murrayanine is a carbazole alkaloid derived from *Murraya koenigii*, which has been used in traditional Chinese medicine in the treatment of cancer. This study aimed to investigate the effects of murrayanine on human lung adenocarcinoma cells *in vitro* and to investigate the mechanisms of its action.

Material/Methods: A549 human lung adenocarcinoma cells and MRC-5 human lung fibroblasts were grown in culture, and an MTT assay determined cell viability. Cells were treated for 24 h with increasing doses of murrayanine (0, 9, 18, and 36 µM). Fluorescence, using 4', 6-diamidino-2-phenylindole (DAPI), acridine orange, ethidium bromide, and propidium iodide (PI), were used for the detection of apoptosis. The cell cycle was studied with fluorescence-activated cell sorting (FACS), and Western blot evaluated protein expression.

Results: Murrayanine treatment resulted in significant dose-dependent inhibition of the growth of A549 cells (p<0.05), with an IC₅₀ of 9 µM, and arrested the cells at the G2/M phase of the cell cycle, reduced the expression of cyclin D and E, CDK2, 4, and 6, and increased the expression of p21 and p27. Murrayanine treatment increased apoptosis of the A549 cells and increased cleaved of caspase-3 and caspase-9, and the Bax/Bcl-2 ratio. Murrayanine treatment increased levels of reactive oxygen species (ROS), disrupted the mitochondrial membrane potential, inhibited invasion, and inhibited phosphorylation of p38 mitogen-activated protein kinase (MAPK) of the A549 cells.

Conclusions: Murrayanine induced cell cycle arrest, oxidative stress, and inhibited the expression of phosphorylated p38 in A549 adenocarcinoma cells.

MeSH Keywords: Apoptosis • Cell Cycle Checkpoints • Cell Migration Assays

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/913873
Background

Recently, there has been increasing research on drug discovery and the development of chemotherapy for the treatment of malignancy [1]. However, clinical use of many anticancer drugs is restricted by their adverse effects [2]. Naturally occurring compounds with anticancer effects have gained attention due to their low toxicity [3]. Murrayanine is a carbazole alkaloid derived from *Murraya koenigii*, which has been used in traditional Chinese medicine in the treatment of cancer [4]. Carbazole alkaloids have been shown to exhibit anticancer effects against a range of cancers [5,6]. However, the effects of murrayanine have not previously been investigated in human lung cancer.

Worldwide, lung cancer remains a leading cause of mortality from malignancy [7]. Lung cancer accounts for approximately 25% of all the cancers and results in up to 20% of cancer-related deaths [8]. The late diagnosis of lung cancer, lack of biomarkers and therapeutic targets, results in an increased need for more effective treatment [9]. Chemoresistance in lung cancer makes it even more difficult to treat [10].

Therefore the aim of this study was to investigate the effects of murrayanine on A549 human lung adenocarcinoma cells in vitro and to investigate the mechanisms of its action.

Material and Methods

Cell lines and culture conditions

The A549 human lung adenocarcinoma cell line and the normal lung fibroblast cell line, MRC-5, were obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA). The cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum, antibiotics (100 units/mL penicillin and 100 µg/mL streptomycin), and 2 mM glutamine. The cells were cultured in an incubator at 37°C with 98% humidity and 5% CO₂ (Thermofisher Scientific, Waltham, MA, USA).

Cell viability assay

At around 70% confluence, the A549 and the MRC-5 cells were seeded in 96-well plates and treated with 0–200 µM of murrayanine (98% purity by high-performance liquid chromatography) (Sigma-Aldrich, St. Louis MO, USA). After 24 hours, the cells were incubated with MTT for 4 h. The media was removed and the colored formazan product was solubilized by 200 µl of dimethyl sulfoxide (DMSO). The viability of the A549 and the MRC-5 cells was then determined at an absorbance at 570 nm.

Apoptosis assays

The A549 cells were grown in 6-well plates (0.6×10⁶ cells/well). Following an incubation period of around 12 hours, the cells were treated with murrayanine for 24 h at 37°C. As the cells detached from the wells, 25 µl of cell cultures were placed onto glass slides and stained with a solution of acridine orange and ethidium bromide, or propidium iodide (PI), or 4’6-diamidino-2-phenylindole (DAPI). The slides were then covered with a coverslip and examined with a fluorescent microscope.

Cell cycle analysis

After incubating the A549 lung cancer cells with increasing concentrations of murrayanine (0, 9, 18, and 36 µM) for 24 h, the cells were washed with phosphate buffered saline (PBS). The A549 cells were stained with propidium iodide (PI) and the distribution of the cells in cell cycle phases was assessed by fluorescence-activated cell sorting (FACS) and flow cytometry.

Reactive oxygen species (ROS) and mitochondrial membrane potential

For determination of the ROS and mitochondrial membrane potential levels, the A549 cells were treated with 0, 9, 18, and 36 µM concentrations of murrayanine for 24 hours and then the ROS and mitochondrial membrane potential levels in the A549 cells were determined, as described previously [11].

Cell invasion assays

The murrayanine-treated A549 cells were seeded onto the Matrigel chamber (1×10⁵ cells/chamber) and inserted into a well of a 24-well plate, followed by the addition of FBS (10%) to the bottom chamber. After 24 h of incubation, the invasive cells on the lower surface of the chamber were stained with crystal violet (0.1%) and the cells were counted.

Western blot

The A549 cells were grown in 6-well plates (0.6×10⁶ cells/well) and incubated in a lysis buffer at 4°C and then incubated at 95°C. The protein content of each cell extract was determined using the Bradford assay. Then, 40 µg of protein was loaded from each sample and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) before being transferred to a polyvinylidene fluoride (PVDF) membrane. The membranes were then washed with TBS and incubated in primary antibodies at 4°C. The cells were treated with appropriate secondary antibodies and the proteins were visualized by enhanced chemiluminescence (ECL) reagent.
Figure 1. Murrayanine inhibited the proliferation of A549 human lung adenocarcinoma cells in vitro. (A) The chemical structure of murrayanine, a carbazole alkaloid. (B) The MTT assay shows the effects of murrayanine on the viability of the A549 lung cancer cells and MRC-5 normal lung fibroblasts. The experiments were performed in triplicate. Data are expressed as the mean ±SD (* P<0.05).

Figure 2. Flow cytometry analysis of murrayanine-treated A549 human lung adenocarcinoma cells show G2/M cell cycle arrest. The experiments were performed in triplicate.
Statistical analysis

Statistical analysis was performed with one-way analysis of variance (ANOVA) followed by Tukey’s test using the SPSS software package, version 9.05 (IBM, Chicago, IL, USA). The values were presented as the mean ±SD. A P-value <0.05 was considered to be statistically significant.

Results

Murrayanine inhibited the proliferation of A549 lung cancer cells

The effects of murrayanine were examined on the A549 lung cancer cells and the normal MRC-5 cells by MTT assay at concentrations ranging from 0–200 µM (Figure 1A). Murrayanine was found to inhibit the growth of the A549 cells in a concentration-dependent manner (Figure 1B). The IC₅₀ of murrayanine treatment of the A549 cells was found be at 9 µM. However, the effects of murrayanine treatment on the proliferation of the MRC-5 cells were negligible. The IC₅₀ of murrayanine against the normal MRC-5 cells was >100 (Figure 1B).

Murrayanine arrested the A549 cells at the G2/M checkpoint

To understand the mechanism of action of the anti-proliferative effects of murrayanine, the distribution of the cell cycle phase in A549 cells was assessed by flow cytometry at 0, 9, 18, and 36 µM concentration of murrayanine. The percentage of G2/M phase cells increased significantly from 5.27% in the control to 33.17% at a concentration of 36 µM of murrayanine (Figure 2). The arrest of the A549 cells at the G2/M phase was associated with alterations in the expression of several of the cell cycle-related proteins. The protein expression of cyclin D, cyclin E, CDK2, CDK4, and CDK6 were reduced following murrayanine treatment (Figure 3A), while the expression of p21 and p27 was significantly increased (Figure 3B).

Murrayanine induced apoptosis of A549 cells

The apoptosis in the murrayanine treated A549 cells was determined by using 4’, 6-diamidino-2-phenylindole (DAPI), acridine orange and ethidium bromide, and propidium iodide (PI) staining. Using the three assays, the percentage of the apoptotic cells increased with increasing concentrations of murrayanine (Figure 4). Apoptosis of the murrayanine-treated A549 cells was further confirmed by examining the protein levels of apoptosis-related proteins by Western blot. Murrayanine treatment increased the cleavage of caspase-3 and caspase-9 in a concentration-dependent manner. Expression of Bax was increased and the expression of Bcl-2 was decreased following murrayanine treatment (Figure 5). The reactive oxygen species (ROS) and mitochondrial membrane potential levels of murrayanine-treated A549 cells were also investigated and the levels of ROS were significantly increased (up to 195% increase) with a decrease in the mitochondrial membrane potential levels (up to 64% decrease) (Figure 6).
Murrayanine inhibited the phosphorylation of p38 mitogen-activated protein kinase (MAPK) in A549 cells

The effects of murrayanine was also examined on the phosphorylation of the p38 mitogen-activated protein kinase (MAPK) by Western blot analysis. Murrayanine inhibited the phosphorylation of p38 in a concentration-dependent manner (Figure 7).

Murrayanine inhibited the invasion of A549 cells

The effect of murrayanine treatment was also investigated on the invasion of the A549 cells by the Matrigel assay. Murrayanine inhibited the invasion of the A549 cells in a concentration-dependent manner. The invasion of the A549 cells decreased by 27% compared with the control cells at a concentration of 36 µM of murrayanine (Figure 8).

Discussion

Worldwide, lung cancer is responsible for high levels of morbidity and mortality [12]. The late diagnosis, lack of diagnostic and therapeutic biomarkers, and poor response by some patients with lung cancer to chemotherapy are all hurdles to treatment [13]. In this study, the effects of murrayanine were evaluated in the A549 lung cancer cell line and the normal MRC-5 lung fibroblast cell line. Murrayanine was found to inhibit the growth of lung cancer cells by triggering G2/M cell cycle arrest and inducing apoptosis. The results suggest that murrayanine may have potential therapeutic effects against lung cancer.
**Figure 7.** The effect of murrayanine treatment of A549 human lung adenocarcinoma cells on the phosphorylation of p38 as shown by Western blot analysis. The experiments were performed in triplicate.

**Figure 6.** Reactive oxygen species (ROS) and mitochondrial membrane potential levels in A549 human lung adenocarcinoma cells treated with murrayanine. (A) Murrayanine treatment of the A549 cells resulted in a significant increase in the levels of reactive oxygen species (ROS). (B) Murrayanine treatment of the A549 cells resulted in decreased mitochondrial membrane potential levels. The experiments were performed in triplicate. The results were expressed as the mean ±SD (* P<0.05).

**Figure 8.** The concentration-dependent effect of murrayanine treatment on the invasion of the A549 lung adenocarcinoma cells. The experiments were performed in triplicate and expressed as mean ±SD (* P<0.05).
cycle arrest. Murrayanine also induced reactive oxygen species (ROS)-mediated reduction in the mitochondrial membrane potential and was associated with apoptotic cell death of the A549 lung cancer cells, with alteration in the protein levels of Bax, Bcl-2, cleaved caspase-3, and cleaved caspase-9. Murrayanine inhibited the phosphorylation of p38 in a concentration-dependent manner. The results of the Matrigel invasion assay showed that murrayanine suppressed the migration of A549 cells.

The findings of the present study are supported by those of previous studies that have shown that several of the carbazole alkaloids inhibit the growth of cancer cells. For example, the carbazole alkaloid, mahanine, has been reported to inhibit the growth of leukemia cells [14]. Carbazole alkaloids have also been reported to inhibit the growth of cancer cells by triggering cell cycle arrest. Mahanimbine has been reported to halt the growth of pancreatic cancer cells by causing G0/G1 arrest [15]. Therefore, in the present study, the effect of murrayanine on the distribution of the cell cycle phase of the A549 cells showed that murrayanine blocked the A549 cells in the G2/M phase of the cell cycle, which was supported by reduced expression levels of cyclin B and cyclin E and upregulation of p21 and p27, which are key regulators of cell cycle [16]. Apart from cell cycle arrest, apoptosis is a mechanism to eliminate cancer cells [15] and in this study, murrayanine was found to induce apoptosis of the A549 cells. Murrayanine also enhanced the cleavage of caspase-3 and caspase-9 and increased the Bax/Bcl-2 ratio. Increased levels of ROS and disruption of the mitochondrial membrane potential have been associated with apoptosis [17]. The findings of the present study showed that murrayanine increased ROS and decreased the mitochondrial membrane potential levels in the A549 cells, supporting cell apoptosis.

Invasion by cancer cells is required for tumor metastasis [18]. Following murrayanine treatment, the inhibition of phosphorylation of p38 mitogen-activated protein kinase (MAPK) and inhibition of invasion of the A549 cells was found in this study. Murrayanine has an antiproliferative effect and may have an effect on tumor invasion.

Conclusions

Murrayanine induced cell cycle arrest, oxidative stress, and inhibited the expression of phosphorylated p38 in A549 adenocarcinoma cells in vitro. Because of its lack of toxicity, further studies are required that include in vivo studies of the effects of murrayanine in lung cancer and other types of malignancy.

Conflict of interest

None.

References:

1. Ohnishi S, Takeda H: Herbal medicines for the treatment of cancer chemotherapy-induced side effects. Front Pharmacol, 2015; 6: 14
2. McQuade RM, Bornstein JC, Nurgali K: Anti-colorectal cancer chemotheraphy-induced diarrhea: Current treatments and side-effects. Int J Clin Med, 2014; 5: 393–406
3. Harvey AI, Edrada-Ebel R, Quinn RJ: The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov, 2015; 14(2): 111–29
4. Ng RC, Kassim NK, Yeap YS et al: Isolation of carbazole alkaloids and coumarins from Aegle marmelos and Murraya koenigii and their antioxidant properties. Sains Malaysia, 2018; 47(8): 1749–56
5. Iman V, Mohan S, Abdelwahab SI et al: Anticancer and anti-inflammatory properties. Sains Malaysiana, 2018; 47(8): 1749–56
6. Samanta SK, Kandimalla R, Gogoi B et al: Phytochemical portfolio and anticancer activity of Murraya koenigii. Drug Des Devel Ther, 2017; 11: 103–21
7. Samanta SK, Konidallama R, Gogoi B et al: Phytochemical portfolio and anticancer activity of Murraya koenigii and its primary active component, mahanimbine. Pharmaco Res, 2018; 129: 227–36
8. Didkowska J, Wojciechowska U, Marczuk M et al: Lung cancer epidemiology: Contemporary and future challenges worldwide. Ann Transl Med, 2016; 4: 1–7
9. Cheng TY, Cramb SM, Baade PD et al: The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. J Thor Oncol, 2016; 11: 1653–71
10. Yoder LH: Lung cancer epidemiology. Medsurg Nurs, 2006; 15: 171–74
11. Miller KD, Siegel RL, Lin CC et al: Cancer treatment and survivorship statistics, 2016. Cancer J Clin, 2016; 66: 271–89
12. Davis JN, Medbery C, Sharma S et al: Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metasta ses from the RSSearch patient registry. Radiat Oncol, 2015; 10: 113
13. Bhattacharya K, Samanta SK, Tripathi R et al: Apoptotic effects of mahanie on human leukemic cells are mediated through crosstalk between Apo-1/Fas signalling and the Bid protein and via mitochondrial pathways. Biochem Pharmacol, 2010; 79(3): 361–72
14. Pei C, He Q, Liang S, Gong X: Mahanimbine exerts anticancer effects on human pancreatic cancer cells by triggering cell cycle arrest, apoptosis, and modulation of AKT/mammalian target of rapamycin (mTOR) and signal transducer and activator of transcription 3 (STAT3) signalling pathways. Med Sci Monit, 2018; 24: 6975–83
15. Chang F, Steelman LS, Shelton IG et al: Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway. Int J Oncol, 2003; 22(3): 469–80
16. Gu ZF, Zhang ZT, Wang J et al: Icarin exerts inhibitory effects on the growth and metastasis of KYSE70 human esophageal carcinoma cells via PI3K/AKT and STAT3 pathways. Environ Toxicol Pharmacol, 2017; 54: 7–13
17. Jin L, Chen J, Pan C et al: Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis. Oncogene, 2017; 36(27): 3797–806

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)